Description
Product Characteristics: Phosphoinositide 3-kinase (PI3K) catalyzes the phosphatidylinositol-3,4,5-triphosphate by phosphorylating phosphatidylinositol (PI), phosphatidylinositol-4-phosphate (PIP), and phosphatidylinositol-4,5-bisphosphate (PIP2). PI3Ks are composed of a catalytic subunit (p110) and a regulatory subunit (p85). The catalytic subunits of PI3K include p110 alpha, p110 beta, p110 gamma, and p110 delta, while the regulatory subunits contain p85 alpha and p85 beta. p85 alpha regulates the catalytic activity of p110 subunit by binding to phosphorylated receptor tyrosine kinases (RTKs) through its SH2 domain. The p85 alpha has been implicated in insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues.PI3 Kinase p85 alpha Antibody is developed in rabbit using a KLH-coupled synthetic peptide within residues 600-50 of human PI3 Kinase p85 alpha (Swiss Prot: P27986).
Target Information: Phosphatidylinositol 3-kinase phosphorylates the inositol ring of phosphatidylinositol at the 3-prime position. The enzyme comprises a 110 kD catalytic subunit and a regulatory subunit of either 85, 55, or 50 kD. This gene encodes the 85 kD regulatory subunit. Phosphatidylinositol 3-kinase plays an important role in the metabolic actions of insulin, and a mutation in this gene has been associated with insulin resistance. Alternative splicing of this gene results in four transcript variants encoding different isoforms. [provided by RefSeq, Jun 2011]